RAFAEL HOLDINGS INC. CLASS B COMMON STOCK

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

13 Mar 2024 16:04:24 By Nasdaq GlobeNewswire

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

14 Dec 2023 15:01:00 By Nasdaq GlobeNewswire

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

30 Oct 2023 15:01:00 By Nasdaq GlobeNewswire

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

13 Jun 2023 15:01:00 By Nasdaq GlobeNewswire

Rafael Holdings Announces up to $5 Million Share Repurchase Program

04 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

14 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

13 Dec 2022 06:00:00 By Nasdaq GlobeNewswire

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

15 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

31 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

28 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

23 Aug 2022 06:43:22 By Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

03 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

06 Jul 2022 07:00:04 By Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022

27 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

16 Jun 2022 13:14:18 By Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

16 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

14 Jun 2022 15:01:00 By Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

01 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

24 May 2022 10:04:10 By Nasdaq GlobeNewswire

Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.

19 May 2022 08:00:02 By Nasdaq GlobeNewswire